APO Research
Talk to an analyst

APO RESEARCH · REPORT

mRNA Vaccines & Therapeutics

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

Selected research

Market Outlook & Growth Opportunities

Global mRNA Vaccines & Therapeutics Market Outlook and Growth Opportunities 2026

28 December 2025192 pages

Choose your research edition.

Industry ResearchmRNA Vaccines & Therapeutics Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal mRNA Vaccines & Therapeutics Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal mRNA Vaccines & Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal mRNA Vaccines & Therapeutics Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal mRNA Vaccines & Therapeutics Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.

Global core mRNA vaccines & therapeutics manufacturers include Moderna Therapeutics, CureVac etc. The top 3 companies hold a share about 65%. Europe is the largest market, with a share about 10%, followed by Asia Pacific and North America.

This report provides an overview of the global mRNA Vaccines & Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of mRNA Vaccines & Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents mRNA Vaccines & Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the mRNA Vaccines & Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.

mRNA Vaccines & Therapeutics Segment by Company

Moderna Therapeutics

CureVac

Translate Bio

BioNTech

Sangamo Therapeutics

Argos Therapeutics

In-Cell-Art

eTheRNA

Ethris

Tiba Biotechnology

mRNA Vaccines & Therapeutics Segment by Type

Infectious Disease Vaccines

Cancer Vaccines

mRNA Vaccines & Therapeutics Segment by Application

Infectious Disease

Cancer

mRNA Vaccines & Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global mRNA Vaccines & Therapeutics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions mRNA Vaccines & Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify mRNA Vaccines & Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze mRNA Vaccines & Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Vaccines & Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of mRNA Vaccines & Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Vaccines & Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the mRNA Vaccines & Therapeutics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global mRNA Vaccines & Therapeutics industry.

Chapter 3: Detailed analysis of mRNA Vaccines & Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of mRNA Vaccines & Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of mRNA Vaccines & Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. mRNA Vaccines & Therapeutics Industry Trends Table 2. mRNA Vaccines & Therapeutics Industry Drivers Table 3. mRNA Vaccines & Therapeutics Industry Opportunities and Challenges Table 4. mRNA Vaccines & Therapeutics Industry Restraints Table 5. Global mRNA Vaccines & Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global mRNA Vaccines & Therapeutics Revenue Share by Company (2021-2026) Table 7. Global mRNA Vaccines & Therapeutics Sales Volume by Company (M Doses) & (2021-2026) Table 8. Global mRNA Vaccines & Therapeutics Sales Volume Share by Company (2021-2026) Table 9. Global mRNA Vaccines & Therapeutics Average Price (USD/Doses) of Company (2021-2026) Table 10. Global mRNA Vaccines & Therapeutics Company Ranking, (2024-2026) & (USD Million) Table 11. Global mRNA Vaccines & Therapeutics Key Company Manufacturing Base & Headquarters Table 12. Global mRNA Vaccines & Therapeutics Company, Product Type & Application Table 13. Global mRNA Vaccines & Therapeutics Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global mRNA Vaccines & Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Infectious Disease Vaccines Table 18. Significant Companies of Cancer Vaccines Table 19. Global mRNA Vaccines & Therapeutics Sales Volume by Type 2021 VS 2025 VS 2032 (M Doses) Table 20. Global mRNA Vaccines & Therapeutics Sales Volume by Type (2021-2026) & (M Doses) Table 21. Global mRNA Vaccines & Therapeutics Sales Volume by Type (2027-2032) & (M Doses) Table 22. Global mRNA Vaccines & Therapeutics Sales Volume Share by Type (2021-2026) Table 23. Global mRNA Vaccines & Therapeutics Sales Volume Share by Type (2027-2032) Table 24. Global mRNA Vaccines & Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global mRNA Vaccines & Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global mRNA Vaccines & Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global mRNA Vaccines & Therapeutics Sales Value Share by Type (2021-2026) Table 28. Global mRNA Vaccines & Therapeutics Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Infectious Disease Table 30. Significant Companies of Cancer Table 31. Global mRNA Vaccines & Therapeutics Sales Volume by Application 2021 VS 2025 VS 2032 (M Doses) Table 32. Global mRNA Vaccines & Therapeutics Sales Volume by Application (2021-2026) & (M Doses) Table 33. Global mRNA Vaccines & Therapeutics Sales Volume by Application (2027-2032) & (M Doses) Table 34. Global mRNA Vaccines & Therapeutics Sales Volume Share by Application (2021-2026) Table 35. Global mRNA Vaccines & Therapeutics Sales Volume Share by Application (2027-2032) Table 36. Global mRNA Vaccines & Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global mRNA Vaccines & Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global mRNA Vaccines & Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global mRNA Vaccines & Therapeutics Sales Value Share by Application (2021-2026) Table 40. Global mRNA Vaccines & Therapeutics Sales Value Share by Application (2027-2032) Table 41. Global mRNA Vaccines & Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Table 42. Global mRNA Vaccines & Therapeutics Sales by Region (2021-2026) & (M Doses) Table 43. Global mRNA Vaccines & Therapeutics Sales Market Share by Region (2021-2026) Table 44. Global mRNA Vaccines & Therapeutics Sales by Region (2027-2032) & (M Doses) Table 45. Global mRNA Vaccines & Therapeutics Sales Market Share by Region (2027-2032) Table 46. Global mRNA Vaccines & Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global mRNA Vaccines & Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global mRNA Vaccines & Therapeutics Sales Value Share by Region (2021-2026) Table 49. Global mRNA Vaccines & Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global mRNA Vaccines & Therapeutics Sales Value Share by Region (2027-2032) Table 51. Global mRNA Vaccines & Therapeutics Market Average Price (USD/Doses) by Region (2021-2026) Table 52. Global mRNA Vaccines & Therapeutics Market Average Price (USD/Doses) by Region (2027-2032) Table 53. Global mRNA Vaccines & Therapeutics Sales by Country: 2021 VS 2025 VS 2032 (M Doses) Table 54. Global mRNA Vaccines & Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global mRNA Vaccines & Therapeutics Sales by Country (2021-2026) & (M Doses) Table 56. Global mRNA Vaccines & Therapeutics Sales Market Share by Country (2021-2026) Table 57. Global mRNA Vaccines & Therapeutics Sales by Country (2027-2032) & (M Doses) Table 58. Global mRNA Vaccines & Therapeutics Sales Market Share by Country (2027-2032) Table 59. Global mRNA Vaccines & Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global mRNA Vaccines & Therapeutics Sales Value Market Share by Country (2021-2026) Table 61. Global mRNA Vaccines & Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global mRNA Vaccines & Therapeutics Sales Value Market Share by Country (2027-2032) Table 63. Moderna Therapeutics Company Information Table 64. Moderna Therapeutics Business Overview Table 65. Moderna Therapeutics mRNA Vaccines & Therapeutics Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 66. Moderna Therapeutics mRNA Vaccines & Therapeutics Product Portfolio Table 67. Moderna Therapeutics Recent Development Table 68. CureVac Company Information Table 69. CureVac Business Overview Table 70. CureVac mRNA Vaccines & Therapeutics Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 71. CureVac mRNA Vaccines & Therapeutics Product Portfolio Table 72. CureVac Recent Development Table 73. Translate Bio Company Information Table 74. Translate Bio Business Overview Table 75. Translate Bio mRNA Vaccines & Therapeutics Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 76. Translate Bio mRNA Vaccines & Therapeutics Product Portfolio Table 77. Translate Bio Recent Development Table 78. BioNTech Company Information Table 79. BioNTech Business Overview Table 80. BioNTech mRNA Vaccines & Therapeutics Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 81. BioNTech mRNA Vaccines & Therapeutics Product Portfolio Table 82. BioNTech Recent Development Table 83. Sangamo Therapeutics Company Information Table 84. Sangamo Therapeutics Business Overview Table 85. Sangamo Therapeutics mRNA Vaccines & Therapeutics Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 86. Sangamo Therapeutics mRNA Vaccines & Therapeutics Product Portfolio Table 87. Sangamo Therapeutics Recent Development Table 88. Argos Therapeutics Company Information Table 89. Argos Therapeutics Business Overview Table 90. Argos Therapeutics mRNA Vaccines & Therapeutics Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 91. Argos Therapeutics mRNA Vaccines & Therapeutics Product Portfolio Table 92. Argos Therapeutics Recent Development Table 93. In-Cell-Art Company Information Table 94. In-Cell-Art Business Overview Table 95. In-Cell-Art mRNA Vaccines & Therapeutics Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 96. In-Cell-Art mRNA Vaccines & Therapeutics Product Portfolio Table 97. In-Cell-Art Recent Development Table 98. eTheRNA Company Information Table 99. eTheRNA Business Overview Table 100. eTheRNA mRNA Vaccines & Therapeutics Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 101. eTheRNA mRNA Vaccines & Therapeutics Product Portfolio Table 102. eTheRNA Recent Development Table 103. Ethris Company Information Table 104. Ethris Business Overview Table 105. Ethris mRNA Vaccines & Therapeutics Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 106. Ethris mRNA Vaccines & Therapeutics Product Portfolio Table 107. Ethris Recent Development Table 108. Tiba Biotechnology Company Information Table 109. Tiba Biotechnology Business Overview Table 110. Tiba Biotechnology mRNA Vaccines & Therapeutics Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 111. Tiba Biotechnology mRNA Vaccines & Therapeutics Product Portfolio Table 112. Tiba Biotechnology Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. mRNA Vaccines & Therapeutics Distributors List Table 116. mRNA Vaccines & Therapeutics Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. mRNA Vaccines & Therapeutics Product Image Figure 2. Global mRNA Vaccines & Therapeutics Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global mRNA Vaccines & Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 4. Global mRNA Vaccines & Therapeutics Sales (2021-2032) & (M Doses) Figure 5. Global mRNA Vaccines & Therapeutics Sales Average Price (USD/Doses) & (2021-2032) Figure 6. Global mRNA Vaccines & Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Infectious Disease Vaccines Image Figure 10. Cancer Vaccines Image Figure 11. Global mRNA Vaccines & Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 12. Global mRNA Vaccines & Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global mRNA Vaccines & Therapeutics Sales Volume Share by Type (2021-2032) Figure 14. Global mRNA Vaccines & Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global mRNA Vaccines & Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global mRNA Vaccines & Therapeutics Sales Value Share by Type (2021-2032) Figure 17. Infectious Disease Image Figure 18. Cancer Image Figure 19. Global mRNA Vaccines & Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 20. Global mRNA Vaccines & Therapeutics Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global mRNA Vaccines & Therapeutics Sales Volume Share by Application (2021-2032) Figure 22. Global mRNA Vaccines & Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global mRNA Vaccines & Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global mRNA Vaccines & Therapeutics Sales Value Share by Application (2021-2032) Figure 25. Global mRNA Vaccines & Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Figure 26. Global mRNA Vaccines & Therapeutics Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global mRNA Vaccines & Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global mRNA Vaccines & Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America mRNA Vaccines & Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 30. North America mRNA Vaccines & Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe mRNA Vaccines & Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 32. Europe mRNA Vaccines & Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific mRNA Vaccines & Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific mRNA Vaccines & Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America mRNA Vaccines & Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 36. South America mRNA Vaccines & Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa mRNA Vaccines & Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa mRNA Vaccines & Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. mRNA Vaccines & Therapeutics Value Chain Figure 124. Manufacturing Cost Structure Figure 125. mRNA Vaccines & Therapeutics Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Infectious Disease Vaccines
  • Cancer Vaccines
Applications
  • Infectious Disease
  • Cancer
Companies covered
  • Moderna Therapeutics
  • CureVac
  • Translate Bio
  • BioNTech
  • Sangamo Therapeutics
  • Argos Therapeutics
  • In-Cell-Art
  • eTheRNA
  • Ethris
  • Tiba Biotechnology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global mRNA Vaccines & Therapeutics Sales Value (2021-2032)
  4. 1.2.2 Global mRNA Vaccines & Therapeutics Sales Volume (2021-2032)
  5. 1.2.3 Global mRNA Vaccines & Therapeutics Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 mRNA Vaccines & Therapeutics Market Dynamics
  1. 2.1 mRNA Vaccines & Therapeutics Industry Trends
  2. 2.2 mRNA Vaccines & Therapeutics Industry Drivers
  3. 2.3 mRNA Vaccines & Therapeutics Industry Opportunities and Challenges
  4. 2.4 mRNA Vaccines & Therapeutics Industry Restraints
3 mRNA Vaccines & Therapeutics Market by Company
  1. 3.1 Global mRNA Vaccines & Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global mRNA Vaccines & Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global mRNA Vaccines & Therapeutics Sales Volume by Company (2021-2026)
  4. 3.4 Global mRNA Vaccines & Therapeutics Average Price by Company (2021-2026)
  5. 3.5 Global mRNA Vaccines & Therapeutics Company Ranking (2024-2026)
  6. 3.6 Global mRNA Vaccines & Therapeutics Company Manufacturing Base and Headquarters
  7. 3.7 Global mRNA Vaccines & Therapeutics Company Product Type and Application
  8. 3.8 Global mRNA Vaccines & Therapeutics Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global mRNA Vaccines & Therapeutics Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 mRNA Vaccines & Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 mRNA Vaccines & Therapeutics Market by Type
  1. 4.1 mRNA Vaccines & Therapeutics Type Introduction
  2. 4.1.1 Infectious Disease Vaccines
  3. 4.1.2 Cancer Vaccines
  4. 4.2 Global mRNA Vaccines & Therapeutics Sales Volume by Type
  5. 4.2.1 Global mRNA Vaccines & Therapeutics Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global mRNA Vaccines & Therapeutics Sales Volume by Type (2021-2032)
  7. 4.2.3 Global mRNA Vaccines & Therapeutics Sales Volume Share by Type (2021-2032)
  8. 4.3 Global mRNA Vaccines & Therapeutics Sales Value by Type
  9. 4.3.1 Global mRNA Vaccines & Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global mRNA Vaccines & Therapeutics Sales Value by Type (2021-2032)
  11. 4.3.3 Global mRNA Vaccines & Therapeutics Sales Value Share by Type (2021-2032)
5 mRNA Vaccines & Therapeutics Market by Application
  1. 5.1 mRNA Vaccines & Therapeutics Application Introduction
  2. 5.1.1 Infectious Disease
  3. 5.1.2 Cancer
  4. 5.2 Global mRNA Vaccines & Therapeutics Sales Volume by Application
  5. 5.2.1 Global mRNA Vaccines & Therapeutics Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global mRNA Vaccines & Therapeutics Sales Volume by Application (2021-2032)
  7. 5.2.3 Global mRNA Vaccines & Therapeutics Sales Volume Share by Application (2021-2032)
  8. 5.3 Global mRNA Vaccines & Therapeutics Sales Value by Application
  9. 5.3.1 Global mRNA Vaccines & Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global mRNA Vaccines & Therapeutics Sales Value by Application (2021-2032)
  11. 5.3.3 Global mRNA Vaccines & Therapeutics Sales Value Share by Application (2021-2032)
6 mRNA Vaccines & Therapeutics Regional Sales and Value Analysis
  1. 6.1 Global mRNA Vaccines & Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global mRNA Vaccines & Therapeutics Sales by Region (2021-2032)
  3. 6.2.1 Global mRNA Vaccines & Therapeutics Sales by Region: 2021-2026
  4. 6.2.2 Global mRNA Vaccines & Therapeutics Sales by Region (2027-2032)
  5. 6.3 Global mRNA Vaccines & Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global mRNA Vaccines & Therapeutics Sales Value by Region (2021-2032)
  7. 6.4.1 Global mRNA Vaccines & Therapeutics Sales Value by Region: 2021-2026
  8. 6.4.2 Global mRNA Vaccines & Therapeutics Sales Value by Region (2027-2032)
  9. 6.5 Global mRNA Vaccines & Therapeutics Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America mRNA Vaccines & Therapeutics Sales Value (2021-2032)
  12. 6.6.2 North America mRNA Vaccines & Therapeutics Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe mRNA Vaccines & Therapeutics Sales Value (2021-2032)
  15. 6.7.2 Europe mRNA Vaccines & Therapeutics Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific mRNA Vaccines & Therapeutics Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific mRNA Vaccines & Therapeutics Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America mRNA Vaccines & Therapeutics Sales Value (2021-2032)
  21. 6.9.2 South America mRNA Vaccines & Therapeutics Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa mRNA Vaccines & Therapeutics Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa mRNA Vaccines & Therapeutics Sales Value Share by Country, 2025 VS 2032
7 mRNA Vaccines & Therapeutics Country-level Sales and Value Analysis
  1. 7.1 Global mRNA Vaccines & Therapeutics Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global mRNA Vaccines & Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global mRNA Vaccines & Therapeutics Sales by Country (2021-2032)
  4. 7.3.1 Global mRNA Vaccines & Therapeutics Sales by Country (2021-2026)
  5. 7.3.2 Global mRNA Vaccines & Therapeutics Sales by Country (2027-2032)
  6. 7.4 Global mRNA Vaccines & Therapeutics Sales Value by Country (2021-2032)
  7. 7.4.1 Global mRNA Vaccines & Therapeutics Sales Value by Country (2021-2026)
  8. 7.4.2 Global mRNA Vaccines & Therapeutics Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt mRNA Vaccines & Therapeutics Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt mRNA Vaccines & Therapeutics Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt mRNA Vaccines & Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Moderna Therapeutics
  2. 8.1.1 Moderna Therapeutics Company Information
  3. 8.1.2 Moderna Therapeutics Business Overview
  4. 8.1.3 Moderna Therapeutics mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Moderna Therapeutics mRNA Vaccines & Therapeutics Product Portfolio
  6. 8.1.5 Moderna Therapeutics Recent Developments
  7. 8.2 CureVac
  8. 8.2.1 CureVac Company Information
  9. 8.2.2 CureVac Business Overview
  10. 8.2.3 CureVac mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 CureVac mRNA Vaccines & Therapeutics Product Portfolio
  12. 8.2.5 CureVac Recent Developments
  13. 8.3 Translate Bio
  14. 8.3.1 Translate Bio Company Information
  15. 8.3.2 Translate Bio Business Overview
  16. 8.3.3 Translate Bio mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Translate Bio mRNA Vaccines & Therapeutics Product Portfolio
  18. 8.3.5 Translate Bio Recent Developments
  19. 8.4 BioNTech
  20. 8.4.1 BioNTech Company Information
  21. 8.4.2 BioNTech Business Overview
  22. 8.4.3 BioNTech mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 BioNTech mRNA Vaccines & Therapeutics Product Portfolio
  24. 8.4.5 BioNTech Recent Developments
  25. 8.5 Sangamo Therapeutics
  26. 8.5.1 Sangamo Therapeutics Company Information
  27. 8.5.2 Sangamo Therapeutics Business Overview
  28. 8.5.3 Sangamo Therapeutics mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sangamo Therapeutics mRNA Vaccines & Therapeutics Product Portfolio
  30. 8.5.5 Sangamo Therapeutics Recent Developments
  31. 8.6 Argos Therapeutics
  32. 8.6.1 Argos Therapeutics Company Information
  33. 8.6.2 Argos Therapeutics Business Overview
  34. 8.6.3 Argos Therapeutics mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Argos Therapeutics mRNA Vaccines & Therapeutics Product Portfolio
  36. 8.6.5 Argos Therapeutics Recent Developments
  37. 8.7 In-Cell-Art
  38. 8.7.1 In-Cell-Art Company Information
  39. 8.7.2 In-Cell-Art Business Overview
  40. 8.7.3 In-Cell-Art mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 In-Cell-Art mRNA Vaccines & Therapeutics Product Portfolio
  42. 8.7.5 In-Cell-Art Recent Developments
  43. 8.8 eTheRNA
  44. 8.8.1 eTheRNA Company Information
  45. 8.8.2 eTheRNA Business Overview
  46. 8.8.3 eTheRNA mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 eTheRNA mRNA Vaccines & Therapeutics Product Portfolio
  48. 8.8.5 eTheRNA Recent Developments
  49. 8.9 Ethris
  50. 8.9.1 Ethris Company Information
  51. 8.9.2 Ethris Business Overview
  52. 8.9.3 Ethris mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Ethris mRNA Vaccines & Therapeutics Product Portfolio
  54. 8.9.5 Ethris Recent Developments
  55. 8.10 Tiba Biotechnology
  56. 8.10.1 Tiba Biotechnology Company Information
  57. 8.10.2 Tiba Biotechnology Business Overview
  58. 8.10.3 Tiba Biotechnology mRNA Vaccines & Therapeutics Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Tiba Biotechnology mRNA Vaccines & Therapeutics Product Portfolio
  60. 8.10.5 Tiba Biotechnology Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 mRNA Vaccines & Therapeutics Value Chain Analysis
  2. 9.1.1 mRNA Vaccines & Therapeutics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 mRNA Vaccines & Therapeutics Sales Mode & Process
  6. 9.2 mRNA Vaccines & Therapeutics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 mRNA Vaccines & Therapeutics Distributors
  9. 9.2.3 mRNA Vaccines & Therapeutics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst